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Abstract
Background: Activation of the Wnt signaling pathway is implicated in aberrant cellular proliferation in various cancers. In
40% of endometrioid ovarian cancers, constitutive activation of the pathway is due to oncogenic mutations in b-catenin or
other inactivating mutations in key negative regulators. Secreted frizzled-related protein 4 (SFRP4) has been proposed to
have inhibitory activity through binding and sequestering Wnt ligands.
Methodology/Principal Findings: We performed RT-qPCR and Western-blotting in primary cultures and ovarian cell lines
for SFRP4 and its key downstream regulators activated b-catenin, b-catenin and GSK3b. SFRP4 was then examined by
immunohistochemistry in a cohort of 721 patients and due to its proposed secretory function, in plasma, presenting the first
ELISA for SFRP4. SFRP4 was most highly expressed in tubal epithelium and decreased with malignant transformation, both
on RNA and on protein level, where it was even more profound in the membrane fraction (p,0.0001). SFRP4 was expressed
on the protein level in all histotypes of ovarian cancer but was decreased from borderline tumors to cancers and with loss of
cellular differentiation. Loss of membrane expression was an independent predictor of poor survival in ovarian cancer
patients (p=0.02 unadjusted; p=0.089 adjusted), which increased the risk of a patient to die from this disease by the factor
1.8.
Conclusions/Significance: Our results support a role for SFRP4 as a tumor suppressor gene in ovarian cancers via inhibition
of the Wnt signaling pathway. This has not only predictive implications but could also facilitate a therapeutic role using
epigenetic targets.
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Introduction
Epithelial ovarian cancer (EOC) is the fifth most common cause
of death from all cancers occurring in women and the leading
cause of death from gynaecological malignancies. Over 75% of
women present with locally advanced or disseminated disease,
typically characterized by a gradual invasion of the surrounding
organs and, in high stage cases, of the peritoneal cavity. Survival
has changed little since the early 1980s despite new chemother-
apeutical drugs. The survival rate of three-quarters of patients
presenting with widespread metastatic disease is only around 20%
[1].
This poor overall prognosis results from a lack of early
symptoms and early diagnosis, ineffective therapy for advanced
disease, resistance to platinum-based chemotherapies and from
limited understanding of the early-initiating events and early stages
of ovarian cancer development. A major challenge remains the
identification of oncogenic ovarian cancer pathways to aid in
diagnosis, as prognostic indicators and as targets for new
therapeutic strategies [2]. Many groups, including our own, have
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iutilized array-based genome-wide discovery platforms to identify
aberrant mRNA expression and somatically acquired DNA
sequence variants or mutations to determine the molecular
changes underlying the development of ovarian cancer, as a first
step to identify molecular markers with potential clinical utility
[3,4].
Using this technology, members of the Wnt signaling pathway
have been implicated in ovarian carcinogenesis, as having the
potential for diagnostic, prognostic and therapeutic targets [5,6].
The Wnt signaling pathway is highly conserved throughout animals
and mediates a variety of cellular functions including cell polarity,
tissue patterning, control of cellular proliferation and development
of neoplasia [7,8]. Wnt proteins are secreted, cysteine rich signaling
molecules with conserved structures. Nineteen Wnt proteins have
been identified and linked to various stages of human development
and carcinogenesis, including cancers of the breast, lung, colon,
ovaries and skin [9,10,11,12,13,14]. The Wnt proteins signal via
Frizzled receptors through a number of different but interconnected
signaling pathways, including the Wnt/Ca
2+, b-catenin and planar-
cell polarity pathways [15,16,17]. In general, the Wnt family is
classified based on ligand and receptor involvement into the
canonical/b-catenin pathway and the b-catenin independent/
non-canonical pathway. Interestingly, non-canonical Wnt signaling
can antagonize canonical Wnt signaling, and may represent a novel
pathway to target cancers driven by canonical Wnt signaling [18].
Downstream target genes of the Wnt/b-catenin/TCF signaling
pathway have been identified as being crucial for ovarian epithelial
cell transformation, and were upregulated in all endometrioid
ovarian cancers with Wnt pathway defects [19,20]. Several other
studies supported this observation, reporting overexpression of
cyclin D1 in ovarian cancers carrying b-catenin mutations
[21,22,23,24].
Secreted frizzled-related proteins (SFRPs) are extracellular
inhibitors of Wnt signaling that act by binding directly to Wnt
ligands [25] or to Frizzled receptors [26]. Frizzled receptors are
found exclusively at the plasma membrane, located at the surface
of Wnt-responsive cells. In recent years, numerous reports have
described epigenetic silencing of these canonical Wnt signaling
antagonists in various human cancers, suggesting they may
function as tumor suppressors [27]. In ovarian cancer, SFRP1
was the first family member reported to be hypermethylated and
silenced in ovarian cancer cell lines and patient specimens but not
in normal controls, suggesting a potential role as a tumor
suppressor [28]. Promoter hypermethylation of SFRP2 and SFRP5
was subsequently also found in ovarian cancer [29]. A recent study
reported loss of SFRP5 expression to be associated with both
progression of ovarian carcinogenesis and chemotherapy resis-
tance [29].
As we had previously identified SFRP4 to be aberrantly
expressed at the RNA level in a large transcriptional profiling
experiment of ovarian cancer patients (unpublished data), here we
investigate for the first time SFRP4 RNA and protein expression in
725 patients using reverse transcription quantitative polymerase
chain reaction (RT-qPCR), Western-blot, immunohistochemistry
(IHC) and capture enzyme-linked immunosorbent assay (ELISA)
in primary cultures, ovarian cell lines, ascites, tissue and plasma.
Methods
Clinicopathological patient cohort
Ethical approval and written informed consent was granted at
three different sites in Switzerland, Germany and Australia: 1.
Department of Gynaecology, University Hospital Zurich and
Department of Gynaecology and Obstetrics, Spital Limmattal,
Zurich (SPUK, StV06/2006, to V.H.S.); 2. Department of
Gynaecology and Obstetrics, University of Schleswig-Holstein
(Ethics Committee of the University of Schleswig-Holstein,
Campus Lubeck; to D.H.); and 3. Gynaecological Cancer Centre,
Royal Hospital for Women, Sydney (HREC 08/09/17/3.02, to
V.H.S.). Archival tissue from 721 patients within the Swiss Cohort
with normal, benign and ovarian/tubal/peritoneal or endometrial
cancers were included in tissue microarrays (281 benign diagnoses,
440 cancers), with the majority of cancers being of ovarian origin
(69.8%; Table 1). Haematoxylin & Eosin (H&E) stained sections of
each sample from both the Swiss and Australian Cohorts were
reviewed by a pathologist specialized in gynaecological pathology
(R.C. for Swiss Cohort; J.S. for Australian Cohort) and areas
corresponding to tumor/benign tissue marked. Tissue core
biopsies of 1.0 or 2.0 mm were incorporated into medium-density
tissue microarrays (Beecher Instruments, Silver Spring, MD,
USA). Each patient was represented by two cores sampled from
different areas of the tumor. Sections from each array were H&E
stained to confirm the inclusion of the selected tissue in each core,
and patients with unclear or mixed histologies excluded. All
clinicopathological patient data such as FIGO stage, grade,
residual disease, presence of ascites, past and present medical
illness, ultrasonographic findings and outcome data were stored in
a specially designed in-house database (PEROV) based on
Microsoft Access (unpublished; Microsoft, Seattle, USA). Patients
with a past history of cancer or inflammatory/autoimmune
diseases were excluded from this study.
Our plasma cohort was extended by 52 patients (German
Cohort) for the purpose of facilitating a larger endometriosis
patient group. Blood samples were collected in EDTA blood tubes
(BD VacutainerH, BD Diagnostics, Franklin Lakes, NJ, USA) prior
to surgery and stored on ice until further processing. Samples were
Table 1. Clinicopathological characteristics of the patient
cohort.
Patient cohort
(n=721)
BENIGN 281 (39%)
Healthy controls 54 (19.2%)
Tube 12
OSE 18
Endometriosis 69 (9.6%)
Benign tumors 158 (56.2%)
INVASIVE/NONINVASIVE TUMORS 440 (61%)
Borderline Tumors 86 (19.5%)
Cancers 354 (80.5%)
Ovarian cancers 247 (69.8%)
Serous 117 (47.4%)
Endometrioid 49 (19.8%)
Clear Cell 49 (19.8%)
Transitional Cell 7 (2.8%)
Mucinous 25 (10.1%)
Type I cancers 223 (50.7%)
Type II cancers 167 (38.0%)
Endometrial cancers 40 (11.3%)
Others 67 (18.9%)
doi:10.1371/journal.pone.0031885.t001
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4uC and plasma stored at 280uC.
Cell culture
Cell line SKOV3 (serous ovarian cancer) was cultured in RPMI
1640 medium containing Penicillin/Streptomycin (Pen/Strep),
10% fetal calf serum (FCS) and L-glutamine (L-Glut). TOV112D
(endometrioid ovarian cancer) and TOV21G (clear cell ovarian
cancer) were cultivated in DMEM+Pen/Strep+10% FCS+L-Glut.
Normal human ovarian surface epithelial cells (HOSE6-3) were
cultured in Medium 199/MCDB 105 (1:2) containing Pen/
Strep+10% FCS+L-Glut. All cancer cell lines were derived from
ATCC (www.atcc.org), HOSE6-3 was a gift from the Garvan
Institute of Medical Research, Sydney, Australia.
Primary cultures
Primary cultures were collected during surgery or repeatedly
during paracentesis required for chemoresistant progressive
disease (Australian Cohort). Ovarian cancer cultures derived
during paracentesis were taken from the cell pellet generated after
centrifugation of ascites at 4uC with 3’000 g. Tubal cells for
culture were collected using a cytobrush at the fimbrial end of the
tube immediately after prophylactic bilateral salpingo-oophorec-
tomy. The two tubal cell lines used in this publication were derived
from two patients undergoing risk-reducing surgery for BRCA1
mutation status (Tube 1) and strong family history of ovarian/
breast cancer (Tube 2), where written informed ethical consent
was granted (HREC 08/09/17/3.02, to V.H.S.). After collection,
cultures were instantly stored in DMEM and transferred to the
laboratory for cultivation. Primary cultures were either grown in
DMEM+Pen/Strep+10% FCS+L-Glut (ovarian cancer cell lines)
or Medium 199/MCDB 105 (1:2) containing Pen/Strep+10%
FCS+L-Glut (normal tubal cell lines) until confluent. The second
passage of each culture was used for the experiments.
RT-qPCR
RT-qPCR was performed according to MIQE guidelines Cells
were grown in 6-well plates (NUNC, Thermo Fisher Scientific,
Roskilde, Denmark) to a confluency of 60%, washed with 16
DPBS (Gibco, Invitrogen Australia Pty Ltd, Mulgrave) and total
RNA extracted (NucleoSpin RNAII kit, Macherey&Nagel, Duren,
Germany). RNA concentration was measured using the Nano-
Drop ND-1000 spectrophotometer (Thermo Fisher Scientific,
Roskilde, Denmark), the integrity confirmed by agarose gel
electrophoresis (1.7% agarose gel) and a ratio of optical density
of 260/230 nm<2.1 (2.0 to 2.2) and 260/280<2.0 (1.8 to 2.2)
selected as inclusion criteria. QPCR was performed on three
reference genes as well as the target gene, SFRP4 using 500 ng
reverse transcribed RNA in a total volume of 20 ml (iScript
Reverse Transcription Supermix, Bio-Rad Laboratories Pty Ltd,
Gladesville, Australia). Primers for reference genes were selected
due to their stable expression: TATA box binding protein [30]
forward 59-TGCACAGGAGCCAAGAGTGAA-39 and reverse
59-CACATCACAGCTCCCCACCA-39; beta-glucuronidase [31]
forward 59-AGCCAGTTCCTCATCAATGG-39 and reverse 59-
GGTAGTGGCTGGTACGGAAA-39; succinate dehydrogenase
complex, subunit A [32] forward 59-TGGGAACAAGAGGG-
CATCTG-39 and reverse 59-CCACCACTGCATCAAATTCA-
TG-39; and SFRP4 forward 59-ACACCCTCTTAAGCAGCAC-
CAG-39 and reverse 59-AGGGTGGATGTCCTGGGAAG-
TAAG-39 [33] (Sigma-Aldrich Pty Ltd, Castle Hill, Australia).
QPCR performed on the Stratagene Mx3005H (Integrated
Sciences Pty Ltd, Chatswood, Australia) using 96-well microtitre
plates (Bio-Rad Laboratories (Pacific) Pty Ltd, Gladesville,
Australia) and the SensiFAST
TM SYBR lo-ROX Kit (Bioline
(Aust) Pty Ltd, Alexandria, Australia) with low ROX as the
fluorescence reference dye. Optimal reaction conditions were
obtained by 26SensiFAST
TM SYBR mix, 400 nM specific sense
primer, 400 nM specific antisense primer, RNase/DNase-free
water and 25 ng cDNA template up to a final volume of 20 ml.
Amplifications were performed starting with 30 sec enzyme
activation at 95uC followed by 40 cycles of denaturation at 95uC
for 5 sec and annealing/extension at 60uC for 30 sec. A melting
curve was subsequently produced at 65–95uC. All samples and
negative controls were amplified in triplicate and the mean of
baseline-corrected normalized fluorescence signals (dRn) obtained
for further calculations. Quantification cycle (Cq) values of our
reference genes were combined in a geometric mean for each
sample [32] and subtracted from SFRP4 expression: DCq=
CqSFRP4-CqRef. To relatively quantify SFRP4 expression (R) in all
studied cell lines, HOSE6-3 was selected as our control and
expressions of other lines were calculated as a ratio compared to
HOSE6-3 as follows: R=2
2[DCqSFRP4- DCqHOSE6-3].
Western-blot analysis
Ascites was collected during paracentesis from two ovarian
cancer patients at two consecutive time points, three months apart.
Tubulin was used as a loading control for cell lines and anti-beta-
2-microglobulin for the patient ascites protein extracts. Aliquots of
30 mg were combined with NuPAGEH LDS sample and reducing
buffers (Invitrogen Australia Pty Ltd, Mulgrave) and boiled before
loading onto sodium dodecyl sulfate (SDS)-polyacrylamide gels.
All gels were electrically transferred to PVDF membranes before
being blocked for 1 h at RT in 0.01% TBS/Tween containing 3%
non-fat milk powder (TBS/Tween with non-fat milk). Membranes
were incubated with primary antibodies overnight at 4uC in TBS/
Tween with non-fat milk and then washed three times for 5 min in
TBS/Tween. Visualization of proteins was performed via the
addition of a secondary antibody conjugated to horseradish
peroxidase (HRP), which was incubated for 1 h at RT in TBS/
Tween with non-fat milk. Membranes were washed three times for
10 min in TBS-Tween, incubated in ECL and developed with
hyperfilm. Scanning and quantification of signal intensities was
performed using a Bio-Rad GS-800 densitometer with Quantity
One software (Hercules, CA, USA). Antibodies were used at the
following dilutions: SFRP4 (Abnova, #6424-A01): 1:1’000,
activated b-catenin (Millipore, #05-665) 1:1’000, b-catenin (Santa
Cruz Biotechnology, #SC-7963), GSK3b (Sigma, #G7914)
1:1’000, anti-beta-2-microglobulin (Sigma, #WH0000567M1,
1:1’000). All secondary antibodies were from DAKO (Dako
Australia Pty Ltd, Botany, Australia) and were used at the
following dilutions: goat anti-rabbit, 1:5’000 and goat anti-mouse,
1:5’000.
Immunohistochemistry
For the detection of SFRP4 expression in various tissues, tissue
microarray slides were analyzed using the Ventana Benchmark
automated staining system (Ventana Medical Systems, Tucson,
Arizona, USA). For antigen retrieval, slides were heated with cell
conditioning solution for 1 h (CC1; Tris-based buffer with slightly
alkaline pH) using a standard protocol. Slides were incubated for
1 h with primary mouse polyclonal anti-human SFRP4 antibody
(1:30; Abnova, Taipeh, Taiwan). Detection was carried out using
the UView HRP system (Ventana Medical Systems, Tucson,
Arizona, USA). Negative controls omitted the primary antibody,
and a positive and negative control tissue for each antibody was
identified from electronic Northern blot data or the published
literature. Counterstaining was performed with hematoxylin and
SFRP4 in Ovarian Cancer
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e318851% acid alcohol. Immunostaining was scored as percentage and
intensity of SFRP4 expression in various cellular compartments
(membrane, cytoplasm, nucleus). Scoring was independently
assessed by two researchers and discrepancies resolved by
consensus. SFRP4 expression from all cores from one patient
was averaged.
ELISA
Serum SFRP4 concentrations were determined by an in–house
developed Sandwich ELISA. Immunoplates (96-well NUNC
MaxiSorp; Thermo Fisher Scientific, Roskilde, Denmark) were
coated with a capturing mouse polyclonal antibody raised against
a partial recombinant human SFRP4 protein (#H00006424-A01,
Abnova, Taipei City, Taiwan) and diluted 1:250 in 0.1 M
phosphate buffer pH 7.2. Coating and incubation were performed
overnight at 4uC. Recombinant protein, primary and secondary
antibodies were diluted in PBS and plates washed three times with
0.05% (v/v) Tween 20 (Sigma-Aldrich Chemie GmbH, Buchs,
Switzerland). Plates were blocked with PBS containing 5% (w/v)
standard commercial available milk powder for 40 min at 37uC
and washed three times. After blocking of unspecific binding sites a
standard curve was developed by using recombinant SFRP4
protein (#H00006424-Q01, Abnova, Taipei City, Taiwan)
ranging from 3’200 ng/ml to 12.5 ng/ml. Undiluted plasma
samples were incubated in duplicate for 1 h at RT. Bound SFRP4
was detected using rabbit polyclonal primary antibody to human
SFRP4 at RT for 60 min (Dr. R. Friis, University of Berne,
Switzerland). Plates were washed three times followed by
incubation with secondary polyclonal anti-mouse antibody
conjugated to rabbit horseradish peroxidase (1:1’000, Abcam,
Cambridge, UK) for 60 min at RT. After five washing steps,
chromogen TMB (Sigma-Aldrich Chemie GmbH, Buchs, Swit-
zerland) was applied as a substrate and the peroxidase reaction
stopped at 30 min by an equal volume of 2 M sulfuric acid.
Optical density was measured using a 450 nm ELISA reader
(Tecan Spectrafluor Plus, Tecan, Mannedorf, Switzerland).
Statistical analysis
Whilst SFRP4 protein expression in tissues was initially
quantified as cytoplasmic, membrane and nuclear staining,
numbers were often too low for further statistical analyses of
individual histological subgroups. Therefore, SFRP4 expression
was combined, independent of the location of staining, and was
called overall ‘‘SFRP4 expression’’ (arbitary units). SFRP4
expression in both tissue and plasma was initially described using
boxplots for various diagnosis groupings. A normal quantile plot
for SFRP4 expression in plasma was indicative of positive skewness
making any subsequent analyses requiring a normal distribution
assumption questionable. However, the variance stabilizing
logarithmic transformation ameliorated the issue. Differences in
SFRP4 expression among diagnosis groups was assessed using a
series of general linear models along with a Bonferroni adjustment
for pairwise comparisons. Possible associations between SFRP4
expression and clinical parameters were assessed using Pearson’s
correlation coefficient. Disease specific survival and relapse free
survival for the expression of SFRP4 were described using Kaplan-
Meier curves and statistical significance was determined using Cox
regression by computing unadjusted and adjusted hazard ratios.
Adjusted Cox models included age categories (#60, .60), tumor
grade (1–2, 3), cancer FIGO stage (I–II, III–IV) and residual
disease (,10 mm, $10 mm). P-values less than 0.05 were
considered statistically significant. Data analyses were generated
using SAS software (v9.2, Cary, NC, USA).
Results
Loss of SFRP4 expression correlates with aggressive
phenotype
SFRP4 was highly expressed in primary tubal cultures when
compared to the normal ovarian surface epithelial cell line
HOSE6-3 and was particularly high in the patient with the
BRCA mutation (Tube 1) as compared to the patient with positive
family history of breast/ovarian cancer (Tube 2; Figure 1 A).
Whilst a clear cell and endometrioid ovarian cancer cell line
(TOV21D, TOV 112D, respectively) expressed SFRP4 at similar
levels to one of the tubal controls, the undifferentiated serous
ovarian cancer cell line (SKOV3) displayed very low levels of
SFRP4 (Figure 1 A). SFRP4 expression was then measured at the
protein level in various healthy and ovarian cancer cell lines by
Western-blot. SFRP4 expression was compared to its key down-
stream regulators activated and total b-catenin. HOSE6-3 was
compared to various ovarian cancer cell lines of different
histotypes and cellular differentiation. SFRP4 expression was lost
in all cancer cell lines compared to HOSE6-3 (Figure 1 B).
Interestingly, TOV112D, the endometrioid ovarian cancer cell
line, expressed highest levels of both activated and total b-catenin,
consistent the known Wnt signaling disruption in endometrioid
cancers (Figure 1 B) [19]. Ascites fluid collected during progressive
chemotherapy resistance was then analyzed for its expression of
SFRP4 and downstream targets as a measure of progression over
time. Using ascites at two consecutive time points from two cancer
patients with supposedly different aggressiveness (Pt 1 mixed
ovarian cancer G1, Pt 2 serous peritoneal cancer G3), these
experiments showed a reduction of SFRP4 protein expression
during progressive chemoresistant disease (Figure 1 C, D). In
parallel with SFRP4 decrease, levels of the downstream Wnt
signaling regulator GSK3b were also reduced, whereas activated
b-catenin increased, suggesting that Wnt signaling was indeed
activated in these patients.
Correlation of SFRP4 tissue expression with various
clinicopathological parameters
SFRP4 localization was then measured at the protein level due
to its proposed function in the membrane, cytoplasm and
occasionally also in the nucleus of cells (Figure 2) using IHC in
a large cohort of 721 patients on tissue microarrays linked to
extensive follow-up data (Table 1). Membranous staining could be
identified at the cell-cell boundary and on the apical membrane,
which is consistent with its suggested secretory function. Our
cohort incorporated 281 control patients who were healthy or had
benign conditions like endometriosis or cystadenomas/-fibromas.
The cancer group also consisted of 440 patients with borderline
tumors or invasive cancers of mostly ovarian (69.8%) but also
endometrial (11.3%) and other origins (18.9%). The mean age at
diagnosis was 57.1 years (19–88 years) for the whole cohort, with
the mean for the control group being five years younger than the
cancer cohort (53.7 vs. 58.9 years). Our comprehensive database
incorporated follow-up data from a maximum period of 29 years
(mean for both cohorts 48.4 months (1–348 months)).
SFRP4 was positively expressed in tissue in 296 of 721 patient
tissues (41.1%) and in 128 of 142 plasma samples (90.1%). Within
the cancer cohort, 279 patients (86.4%) had high grade tumors
(grade 3) and 221 patients (55.3%) presented with advanced
(FIGO III/IV) stage disease. The five year mortality rate in the
whole cancer/Type I/Type II cohort was 29.5/20.6/41.3%,
respectively. The five year relapse rate in the same cohort
subgroups was 20.5/15.3/27.5%, respectively, thus reflecting a
representative cancer cohort.
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both in tissue and plasma, with clinicopathological parameters
derived from our in-house clinicopathological database (PEROV
database; Access (Microsoft, Seattle USA)) was assessed using
Pearson’s correlation coefficient, r. Clinicopathological parameters
which were accessible within our cohort included abortions, age at
diagnosis, BMI, CA125 levels, CA72-4 levels, HE4 levels, grade
and stage of the cancers, residual disease, ascites at diagnosis, size
and bilaterality of ovarian tumors, performance status at diagnosis,
length of follow-up, disease-specific and relapse-free survival,
platinum chemotherapy, oral contraceptive or hormone replace-
ment therapies, pregnancies/deliveries, age at menarche and
menopause, presence of acne, polycystic ovaries, excess hair,
infertility, infections, diabetes, hypertension, alcohol/drug intake,
smoking, intake of non-steroidal drugs, past history of hospital-
izations, breast disease, endometriosis, fibroids, ovarian cysts, and
past history of cancer or familial cancers.
The only moderately strong correlation found for SFRP4
expression both in tissue and plasma was detected in the case of
ascites being present at first diagnosis (SFRP4 IHC: r=0.55,
p=0.01; SFRP4 ELISA: r=20.60, p=0.03). Another moderately
strong correlation was present for breastfeeding when correlated to
SFRP4 plasma expression (r=20.79, p=0.06). However, this is of
borderline significance as the sample size for breastfeeding was
rather small. Weak correlations were found for BMI (SFRP4 IHC:
r=0.19, p=0.003) and the new tumor marker HE4 (SFRP4
ELISA: r=20.25, p=0.02) [34]. A marginally significant
relationship could be detected for past history of gynaecological
operations (IHC: p=0.038, ELISA: p=0.099), hormone replace-
ment therapy (ELISA: p=0.097) and alcohol intake (IHC:
p=0.098).
SFRP4 expression is increasingly lost during malignant
transformation
As would have been envisaged from its supposed function,
SFRP4 expression presented particularly as membrane and
cytoplasmic staining. From all tissues examined, only the fimbrial
end of the fallopian tube expressed nuclear SFRP4 staining, which
was a rather unexpected finding (Figure 2 B). Ovarian surface
epithelium, which was until recently proposed to be the uniform
place of origin for most ovarian cancers, displayed only minimal
cytoplasmic and no membrane staining, as was the case for
inclusion cysts, the location of metaplastic changes within the
ovary. The highest SFRP4 expression within all studied tissues was
found in the tubal epithelium, which is consistent with our findings
at the RNA level in primary tubal cultures (Figure 1 A). The newly
proposed Type II cancers are increasingly thought to have their
origin at the fimbrial end of the fallopian tube, which should then
rather be the normal control for most cancers (38). Indeed, we
found a decline in cumulative SFRP4 expression from tubal
epithelium, benign tissues (including ovarian surface epithelium
and inclusion cysts), endometriosis to borderline tumors and
Figure 1. SFRP4 expression in cell lines, primary cultures and ascites. Loss of SFRP4 expression from primary tubal epithelial cell lines
towards ovarian cancer cell lines is shown in various experimental settings. (A) We have applied fluorescence based RT-qPCR to investigate SFRP4
gene expression in primary tubal (healthy patients) and immortalized cell lines. HOSE6-3 was selected as control and expressions of other cell lines
were calculated as a ratio compared to HOSE6-3: R=2
2[DCqSFRP4- DCqHOSE6-3]. (B) SFRP4 and its downstream targets activated b-catenin (ABC), b-
catenin and GSK3 b were measured by Western-blot in various cell lines (HOSE6-3, TOV21G (clear cell, Type I ovarian cancer), TOV112D (endometrioid)
and SKOV3 (serous) Type II ovarian cancers) as well as in (C) ascites samples from high grade serous ovarian cancer patients with chemoresistance,
collected at two consecutive time points during disease progression (TP, time point shown as Western-blot; B2M, beta-2-microglobulin was used as
loading control). (D) Results for SFRP4, activated b-catenin (ABC), b-catenin, GSK3 b are presented quantitatively using densitometric analysis from
one experiment on patient ascites samples.
doi:10.1371/journal.pone.0031885.g001
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found by RT-qPCR in cell lines (Figure 1 A). Loss of SFRP4
expression from benign to cancer was statistically significant both
when measured as membrane expression alone (p,0.0001 overall,
Figure 3.2; Benign vs. Cancer, p=0.07; Borderline vs. Cancer,
p,0.0001) and when membrane, cytoplasm and nuclear expres-
sion were measured in combination (p=0.0004 overall, Figure 3.1
A; Benign vs. Cancer, p=0.039; Borderline vs. Cancer, p=0.002).
Whilst a subdivision of membrane staining was difficult to measure
due to small sample sizes in membrane-expressing tissues, the
highest expression in the benign group for the total SFRP4
expression was in the tubal epithelium, followed by endometriosis
and lowest in ovarian surface epithelium and inclusion cysts
(Figure 3.1 B; Tube vs. OSE, p,0.0001; Tube vs. Endometriosis,
p=0.014).
We did not only detect SFRP4 in tissues but also established
an ELISA for SFRP4 detection in plasma. Its detection in
human plasma, for the first time described here, is consis-
tent with its proposed secretory function, and showed the same
trend as in tissues (p=0.03, Figure 3.1 C; Benign vs. Cancer,
p=0.025).
In contrast to previous literature on endometrioid endometrial
cancers, SFRP4 expression was similarly distributed in all
histological subtypes of ovarian cancer (Figure 4 A), although in
plasma, patients with endometrioid ovarian cancers showed a
trend towards higher SFRP4 expression (N.S. p=0.23; Figure 4
C). Due to reported Wnt signaling defects in endometrioid
endometrial cancers we included these adenocarcinomas into our
analysis and could demonstrate a lower expression in endometrial
cancer patients compared to the control cohort, both in tissue and
plasma samples (Figure 4 B & D). When ovarian cancers were split
into the newly proposed ovarian cancer Type I and II groups (38),
Type II ovarian cancers expressed lower levels of SFRP4, which is
consistent with the proposed progression model where Type II
cancers have frequent p53 mutations and present as the more
aggressive and rapidly progressing type of ovarian cancer. This
trend, however, whilst observed in both tissue (overall and
membrane expression) and plasma, was only significant in the
later (p=0.014 overall, Figure 4 D; Benign vs. EOC Type II,
p=0.007)).
No loss in expression could be found between early (I/II) and
advanced (III/IV) FIGO stages (p=0.86; data not shown), but
SFRP4 tissue expression decreased with loss of cancer differenti-
ation showing significantly lower levels in undifferentiated
compared to well differentiated cancers (p=0.006 overall; G1 vs.
G2, p=0.004; G1 vs. G3, p=0.017; data not shown).
Loss of SFRP4 membrane expression is associated with
poor survival
Patients with cancers who had lost membrane SFRP4
expression were associated with an earlier death from their disease
(p=0.016, Figure 5 A). This effect was still present (p=0.089)
when SFRP4 was modeled against strong predictors of outcome in
ovarian cancer like age, stage, grade and residual disease (p-values
0.0062; 0.014; 0.22; ,0.0001, respectively). No similar predictive
power was possible for all SFRP4 (combining membrane,
cytoplasmic and nuclear staining; p=0.50) or SFRP4 expression
in patient’s plasma. The same result could be found when only
ovarian/tubal and peritoneal cancers were examined as the
number of SFRP4 positive cancers changed only by 3 when other
cancers were excluded. Therefore, the effect seen here is clearly
ovarian cancer related.
The independent prediction of membranous SFRP4 expression
in the 5 year mortality of gynaecological cancer patients has a
factor of 1.8, which means that the chance of dying earlier of
cancer is 80% higher if SFRP4 membrane staining is absent in
their tumors at the time of diagnosis. The power of this prediction
within the multivariable model becomes obvious when a strong
predictor of prognosis like grade becomes insignificant after adding
SFRP4 (p=0.21). Moreover, the other highly predictive clinical
factors like age, stage and residual disease have similar hazard
ratios and predictive powers (risk 60.6 (age), 62.2 (stage), 63.2
(residual disease)). No significant prediction was found for relapse-
free survival although it showed a similar trend (Figure 5 B).
Discussion
We previously performed transcription profiling in ovarian
cancer specimens compared to normal ovarian controls [3] which
revealed aberrant expression of SFRP1 and SFRP4 in ovarian
cancers. A relationship between down-regulation of SFRP1 and
SFRP4 and microsatellite instability is known for endometrial
cancers. SFRP4 also suppresses, depending on the receptor, Wnt-
Figure 2. SFRP4 protein expression measured by immunohis-
tochemistry. IHC demonstrating representative SFRP4 protein expres-
sion at two magnifications (610 left column, 640 right column) in
normal tissues (ovarian surface epithelium (A) and tubal epithelium (B))
and various types of ovarian cancers (endometrioid (C), serous (D) and
clear cell (E)).
doi:10.1371/journal.pone.0031885.g002
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in endometrial cancer cell lines [35,36]. Conversely, up-regulation
of SFRP4 was observed for breast, colorectal and prostate cancers
which were associated with an increase in cytoplasmic b-catenin
levels. Its membrane localization has also been correlated with a
good prognosis in various cancers [37].
In this study, we could detect the same survival effect for the first
time in a large cohort of adenocarcinomas of gynaecological
origin. This effect was present for membranous SFRP4 expression
but only had an effect on survival, not on recurrence of the patient.
Our experiments contradict a previous small study where SFRP4
expression was measured by IHC in 153 serous ovarian cancers
and no survival effect could be found [38]. The advantage of our
cohort, however, is the large amount of specimens and the long-
term follow-up of 29 years which makes this prediction possible.
We observed the highest SFRP4 expression at both the RNA
and protein level in tubal epithelium whilst only low or no
membrane expression at all could be found in ovarian surface
epithelium. The high protein SFRP4 expression in tubal
epithelium was due to membrane, cytoplasmic and particular
nuclear staining, which was striking as SFRP4 is only supposed to
have an extracellular role. Whilst the low detection rate of
membrane staining in ovarian surface epithelium could be due to
the thin layer of mesothelial cells, certainly nuclear staining could
have been clearly visible but was instead absent. It is unclear at this
point why this obvious tubal nuclear staining was observed. Tubal
Figure 4. SFRP4 tissue and plasma expression in various diagnoses. Boxplots representing total SFRP4 expression in tissues of various
ovarian cancer histotypes shows no significant difference (A). A trend of decreasing expression from benign tumors (Benign) to endometrial cancers
(Endo Cancer) and ovarian cancers (EOC) Type II can be seen both in tissue (B) and plasma (D). SFRP4 plasma expression was highest in endometrioid
ovarian cancers compared to serous and transitional cell cancers (C).
doi:10.1371/journal.pone.0031885.g004
Figure 3. SFRP4 tissue and plasma expression from benign towards cancer. Boxplots representing cumulative SFRP4 expression (arbitrary
units) in cytoplasm, membrane and nucleus (SFRP4 Expression in Tissue; 3.1 A) and SFRP4 Expression (Log(SFRP4 Expression) in Plasma; 3.1 C) in
plasma of patients with benign diagnosis, borderline tumors and cancers. Subdivision of the benign diagnosis group shows highest tissue expression
in tubal epithelium (Tube) compared to ovarian surface epithelium (OSE) and endometriosis (3.1 B) and similar expression levels in the plasma of
healthy patients (Healthy) and patients with benign tumors and endometriosis (3.1 D). Membrane-only expression of SFRP4 shows highest expression
in benign tissue with a decrease in borderline tumors and a marked reduction in cancers (3.2).
doi:10.1371/journal.pone.0031885.g003
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known that overexpression of SFRP4 shifts prostate cancer cell
lines toward an epithelial morphology [39,40]. On the other hand
the lowest SFRP4 levels were found in Type II ovarian cancers
(advanced stage/undifferentiated serous cancers and carcinosar-
coma), which are increasingly thought to be a distinct molecular
entity from the less aggressive Type I ovarian cancers [41]. This
conjoint finding of highest SFRP4 expression in tubal epithelium
and lowest in Type II ovarian cancers fits optimally to the
proposed model that Type II cancers derive rather from the tubal
epithelium and not the ovarian surface epithelium. The loss of
expression not only from borderline tumors towards aggressive
phenotype ovarian cancers but also from what is supposed to be
the site of origin (fimbrial end of the fallopian tube) towards the
cancer also strengthens the proposed putative inhibitory function
of SFRP4 within the Wnt signaling pathway. In a recent study, loss
of SFRP5 has been associated with both ovarian carcinogenesis
and chemotherapy resistance [29]. Moreover, overexpression of
SFRP4 also inhibited proliferation and metastatic potential in
prostate cancers and was an independent predictor of outcome
[37,42,43]. The loss of SFRP4 expression in our study of ovarian
oncogenesis supports the results found in other cancers and
suggests a tumor suppressor function for SFRP4 also in ovarian
cancers. Loss of this function results in a more aggressive
phenotype which could be found in patients with progressive
chemoresistant disease, again in consistency to reports in other
cancers (27).
Apart from confirming an inhibitory effect of SFRP4 in all
histotypes of ovarian cancer, this study also demonstrated for the
first time that the secreted levels of SFRP4 can indeed be detected
in human blood and can therefore be used diagnostically. Whilst
SFRP4 plasma expression was not predictive of outcome, its loss of
expression from healthy to cancer still supports the findings
achieved by RT-qPCR, Western-blot and IHC, and is probably
mainly due to lower sample size and shorter follow-up data than
our large IHC cohort.
This study suggests that both on gene and protein expression
level patients with disrupted function of SFRP4 might be able to
be targeted by antagonizing the Wnt signaling pathway. As gene
expression of SFRP members is often lost through promoter
hypermethylation, re-expression of these gatekeepers through the
use of epigenetic modifying agents could be one way of
antagonizing activated canonical Wnt signaling. The importance
of these Wnt gatekeepers has been demonstrated in colorectal
cancer, the cancer most commonly associated with aberrant Wnt
signaling where re-expression of Wnt antagonists appeared to
override strong downstream mutations in APC (adenomatous
polyposis coli), and induce apoptosis [44]. Another approach of
inhibiting cancers with hyperactivated canonical Wnt signaling,
such as ovarian cancer, may be by activating the antagonistic non-
canonical Wnt pathway by targeting key receptors or ligands. One
gene which could be targeted in this antagonistic pathway is Wnt-
5a, which has been shown to act as a suppressor of tumor
metastasis in breast cancers [45]. We and others have recently
shown that Foxy-5 peptide, a six amino acid fragment based on
Wnt-5a, with subsequent modifications has anti-metastatic prop-
erties [46].
This study adds to the growing body of literature highlighting
the importance of these Wnt gatekeepers in ovarian cancer. It also
demonstrates the clinical relevance of SFRP4, a proposed putative
inhibitor of the Wnt signaling pathway for both prognosis as well
as potentially therapeutic target in ovarian cancer. This is of major
importance particularly in the supposedly low risk Type I ovarian
cancers where it is crucial to identify patients which will develop
aggressive disease despite having a low risk cancer where otherwise
adjuvant chemotherapy might not even be administered.
Figure 5. Loss of SFRP4 membrane expression results in poor
patient outcome. Kaplan-Meier Curves for disease specific survival (A)
and relapse free survival (B) of patients whose tumors have SFRP4
membrane expression (#) or have lost expression (6). Loss of
expression is significantly correlated with earlier death of disease as
measured using Cox regression by computing unadjusted and adjusted
hazard ratios.
doi:10.1371/journal.pone.0031885.g005
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